UPenn Perelman School of Medicine: Real-World Data Suggests Stopping Immunotherapy After Two Years is Reasonable in Patients With Advanced Lung Cancer
June 05, 2023
June 05, 2023
CHICAGO, Illinois, June 5 (TNSjou) -- The University of Pennsylvania's Perelman School of Medicine issued the following news release:
* * *
Penn Medicine study finds indefinite immunotherapy is not associated with improved survival in large, retrospective cohort
* * *
Over the past decade, the approval of immune checkpoint inhibitors has revolutionized treatment for patients with advanced lung cancer, helping many live longer lives and improvin . . .
* * *
Penn Medicine study finds indefinite immunotherapy is not associated with improved survival in large, retrospective cohort
* * *
Over the past decade, the approval of immune checkpoint inhibitors has revolutionized treatment for patients with advanced lung cancer, helping many live longer lives and improvin . . .